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Acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23; AC) is the lipid hydrolase responsible for the degradation of ceramide into
sphingosine and free fatty acids within lysosomes. The enzymatic activity was first identified over four decades ago, and is deficient in the
inherited lipid storage disorder, Farber Lipogranulomatosis (Farber disease). Importantly, AC not only hydrolyzes ceramide into sphingosine, but
also can synthesize ceramide from sphingosine and free fatty acids in vitro and in situ. This “reverse” enzymatic activity occurs at a distinct pH
from the hydrolysis (“forward”) reaction (6.0vs. 4.5, respectively), suggesting that the enzyme may have diverse functions within cells dependent
on its subcellular location and the local pH. Most information concerning the role of AC in human disease stems from work on Farber disease.
This lipid storage disease is caused by mutations in the gene encoding AC, leading to a profound reduction in enzymatic activity. Recent studies
have also shown that AC activity is aberrantly expressed in several human cancers, and that the enzyme may be a useful cancer drug target. For
example, AC inhibitors have been used to slow the growth of cancer cells, alone or in combination with other established, anti-oncogenic
treatments. Aberrant AC activity also has been described in Alzheimer's disease, and overexpression of AC may prevent insulin resistant (Type II)
diabetes induced by free fatty acids. Current information concerning the biology of this enzyme and its role in human disease is reviewed within.
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Acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23;
AC) was originally identified in rat brain homogenates by Gatt
in 1963 [1], but the first substantial purification of the enzyme
did not occur until 1995, when the protein was isolated from
human urine [2]. The purified polypeptide was ∼50kDa and
could be reduced into 13 and 40kDa α- and β-subunits,
respectively [2]. Peptido-N-glycanase and Endo-H further
reduced the molecular weight of the β-subunit, suggesting the
presence of 5 or 6 N-linked oligosaccharide chains. In contrast,
the α-subunit was not glycosylated. These findings were
subsequently confirmed by site-directed mutagenesis of the
full-length AC cDNA [3].
Although the amount of purified, urinary enzyme obtained in
these studies was small, it was enough to carry out preliminary
characterization studies and to produce the first anti-AC
polyclonal antibodies. These antibodies were subsequently
used to investigate the enzyme's biosynthesis in cultured skin
fibroblasts [3], revealing that AC was initially synthesized as a
∼55kDa precursor polypeptide that was proteolytically pro-
cessed into the α- and β-subunits within lysosomes. A portion
of newly synthesized AC also was secreted from the cells as a
monomeric protein of ∼47kDa. At the present time the
proteolytic enzyme(s) responsible for processing AC into the
individual subunits remain unknown, as does the precise
subcellular localization of the precursor and processed AC
forms.
2. Isolation of AC cDNA and genomic sequences
The full length, human AC cDNAwas isolated from cultured
skin fibroblasts and pituitary tissue in 1996 [4]. The full-length
sequence was 2312-bp and contained an open reading frame
(ORF) of 1185-bp encoding a 395 amino acid polypeptide. Both
the α and β-subunits were encoded by the same cDNA. The
human AC gene, mapped to the short arm of chromosome
8 (p21.3–22), spanned ∼30-kb and included 14 exons and 13
introns [5]. The murine AC cDNA was ∼80% identical to the
human cDNA, and the protein shared ∼90% homology with its
human counterpart [6].
3. Production and characterization of recombinant AC
To produce and characterize large quantifies of AC, the
human enzyme was overexpressed in Chinese hamster ovary
(CHO) cells by amplification of the transfected, full-length
cDNA [7]. The majority of the overexpressed enzyme was
secreted into the culture media and purified by sequential
chromatography using Concanavalin A, Blue Sepharose and
Superose 12. The purified, recombinant protein contained the
same α- and β-subunits as human AC purified from natural
sources (see above), had an acidic pH optimum when
determined in vitro (4.5), and followed normal Michaelis–
Menten kinetics using two different substrates, [14C]-labeled
C12 ceramide ([Lauryl-1-14C]D-erythro sphingosine) and
BODIPY-conjugated C12 ceramide. Deglycosylation studiesshowed that the purified, recombinant enzyme contained mostly
“high mannose” type oligosaccharides which were present
on the β-subunit. The β-subunit also had two distinct
polypeptide backbones that differed in molecular mass by
∼2–4kDa. Amino acid sequence analysis revealed a single N-
terminus, suggesting that the different peptide backbones were
likely due to carboxy-terminal processing.
4. Identification and characterization of the reverse
ceramidase activity
In 1963 Gatt suggested that partially purified, brain AC
could synthesize ceramide from free fatty acids and sphingosine
[1]. However, due to the substantial contaminants present in
these early enzyme preparations, it remained unclear whether
the hydrolysis (“forward”) and “reverse” reactions were in fact
carried out by the same polypeptide. In 2003 Okino et al. [8]
showed that the highly purified, recombinant AC could carry
out the reverse reaction in vitro using [14C]-labeled C12 fatty
acid ([1-14C]lauric acid) and sphingosine as substrates. In
contrast to the degradative reaction, the “reverse” activity
occurred at an optimal, in vitro pH of ∼6.0. Non-ionic
detergents and zinc cations inhibited this activity, whereas
most other cations were stimulatory. Of note, sphingomyelin
also was very inhibitory towards this reaction, while the anionic
lipids, phosphatidic acid and phosphatidylserine, were stimu-
latory. Of various sphingosine isomers tested in the reverse
reaction, only the natural, D-erythro form could efficiently serve
as a substrate in the reverse reaction. The preferred fatty acid
was lauric acid.
To confirm these findings, reverse ceramidase activity was
determined in cell lysates from a Farber disease patient, and was
reduced to the same extent as the degradative activity [8]. This
demonstrated that both the forward and reverse AC activities
were derived from the same gene product. Furthermore, when
fluorescently (NBD)-conjugated lauric acid and sphingosine
were added to cultured lymphoblasts from a Farber disease
patient, the conversion to NBD-ceramide was reduced ∼30%
when compared to normal cells. Thus, these results confirmed
initial observations reported over 40years ago on the reverse
ceramidase reaction, and further revealed that AC plays a
critical role in the regulation of ceramide and sphingosine
metabolism.
5. Characterization of a multienzyme complex containing
AC, acid sphingomyelinase and β-galactosidase
Notably, when media from CHO cells genetically engi-
neered to over-express human AC were analyzed, a large
amount of acid sphingomyelinase (ASM) activity was found
[7]. Compared to parental CHO cells, the increase in ASM
activity was 20-fold or greater. This was not due to increased
expression of the CHO ASM gene, and it was therefore
reasoned that some of the endogenous, CHO-derived ASM was
associating with the overexpressed, human AC in these cells,
and that the two enzymes were being released into the culture
media together. To confirm that this was not an artifact of the
Table 1
Historical landmarks in the study of acid ceramidase
1963 Enzyme first discovered and partially purified by Gatt
1963 “Reverse” ceramidase reaction first identified
1972 Deficiency of acid ceramidase first found in Farber disease patients
1995 First substantial purification of acid ceramidase from human urine
1996 First cloning of the human acid ceramidase cDNA
1996 First mutation identified in a Farber disease patient
1999 First cloning of the human acid ceramidase gene
2002 First production of recombinant, human acid ceramidase
2002 First acid ceramidase “knock-out” mouse model constructed
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overexpressed in Farber disease cells, and the same observa-
tions were made.
Anti-AC antibodies were subsequently used to immunopre-
cipitate AC from the CHO and normal skin fibroblast cell
culture media, and the activities of several other lysosomal
hydrolases were measured. In addition to AC activity, high
levels of ASM activity were found in these precipitates, as well
as the activity of β-galactosidase [7]. These findings were
important since they revealed: (a) that the association of AC and
ASM was strong enough to permit co-precipitation, and (b) at
least one other enzyme was present in this complex (β-
galactosidase). It is notable that there are two β-galactosidases
in cells, one of which uses galactosylceramide as substrate. It is
also important to note that the activities of several other
lysosomal enzymes (e.g., alpha iduronidase, alpha galactosi-
dase, etc.) were not elevated in these immunoprecipitates,
indicating the specificity of this complex.
6. Farber disease
The first case of Farber disease (Farber Lipogranulomatosis;
FD) was described and characterized in 1957 by Sidney Farber
[9], but it was not until 1972 that the inherited deficiency of AC
activity was found to be the cause of this disorder [10] (Table 1).
Based on the clinical severity and sites of major tissue
involvement, FD has been classified into 7 subtypes [11]. In
most cases, the disease is diagnosed early in life with typical
symptoms including deformed joints, subcutaneous nodules,
and progressive hoarseness. Type 1 patients have a very severe
phenotype and most die by 2 years of age. A majority have
neurological involvement in addition to the characteristic
findings mentioned above. Types 2 (Intermediate) and 3
(Mild) FD patients have less severe phenotypes and may
survive longer. Type 4 FD is an extremely rare, neonatal form of
the disease that presents in infancy with hepatosplenomegaly
and leads to death by 1 year of age. Only 6 patients with this
form have been described. Type 5 FD is characterized by
progressive neurologic deterioration and survival up to 5 years
of age. Type 6 FD is an unusual entity in that only one patient
has been described who inherited mutations in two distinct
genes, acid ceramidase and the β-subunit of hexosaminidase.
Type 7 FD is actually not FD at all, but rather occurred in a
patient carrying mutations in the gene encoding the prosaposin
polypeptide. Since there was a profound reduction in AC
activity in this individual and clinical symptoms similar to FD,
this “experiment of nature” demonstrated for the first time that
AC requires an intact prosaposin gene for in vivo function
[12,13]. Subsequent studies went on to demonstrate that SAP-D
was required for optimal AC activity [14,15].
FD is diagnosed by the demonstration of reduced AC
activity, abnormally high ceramide levels in cultured cells,
biopsy samples or urine, and the presence of “Farber bodies”,
comma-shaped curvilinear tubular structures, by electron
microscope analysis. FD is a very rare autosomal recessive
disorder, and less than 100 cases have been reported since the
first description in 1957. Due to the extremely small patientpopulation, the natural history and underlying pathophysiology
of this disease is poorly described.
To date a total of 17 different mutations in the AC gene
have been found in FD patients ([4,5,16–18]; see Fig. 1). Of
these 17 mutations, 12 are point mutations leading to single
amino acid substitutions, 3 are due to small deletions within
the AC gene, 1 is due to a premature termination, and 1 results
in an abnormal fusion protein. As with other storage disorders,
the distinct clinical presentation of individual FD patients is
likely due to the specific mutations inherited in the AC gene.
However, at the present time the clinical course cannot be
accurately predicted from the genotype, nor can it be closely
correlated with the amount of residual AC activity in cultured
cells.
7. Construction and characterization of an AC
“knock-out” mouse
A complete “knock-out” AC mouse model was created in
2002 by Li et al. [19]. To generate this model, an AC targeting
vector was constructed and used to obtain F1, heterozygous
animals. Notably, genotype analysis of over 150 offspring or
embryos from these heterozygous intercrosses revealed an
absence of −/− individuals at developmental day E8.5 or later.
Thus, the first important observation from these studies was that
homozygosity for the mutant allele led to an early, embryonic
lethal phenotype. This observation was confirmed by generating
a second line of AC knock-out mice using a different, targeted
ES cell clone. There were two possible explanations for this
outcome: either the −/− embryos were not being formed (due to
changes in the −/− gametes that prohibited fertilization), or the
embryos were being formed, but died before E8.5. Of note,
several resorbed embryos were observed in the pregnant
females from these matings, but these could not be accurately
genotyped due to maternal contamination following dissection.
Studies are ongoing to investigate the mechanism(s) leading to
the lethal phenotype.
The second surprising observation obtained from these
studies was that as the +/− breeding pairs were mated over time,
the ratio of +/+ to +/− pups from these intercrosses shifted from
the expected 1:2 ratio to a ratio of 1:10 or more. Thus, as the +/−
animals aged, they generated predominately +/− offspring. This
observation also was confirmed by analysis of the second,
independent AC knock-out line. One hypothesis to explain this
finding is that as +/− animals age, they accumulate lipids in their
Fig. 1. Schematic depiction of the known mutations in the human acid ceramidase gene causing Farber disease. The 14 exons of the gene are indicated by the black
boxes. Mutations are listed below the exons.
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hypothesis is supported by the observation that several organs
of +/− animals, including ovarian tissue, exhibited substantial
lipid storage over time [19]. One working theory is that the
mutant gametes (male or female) in +/− parents may have
abnormal lipid membranes (presumably more hydrophobic due
to sphingolipid and cholesterol storage), and that this, in turn,
may provide them with a fertilization advantage.
Of particular relevance to these findings is the fact that
ceramide metabolism plays a key role in oocyte development
[20]. For example, in the human ovary ceramide levels are
increased immediately following menopause, when a woman's
pool of oocytes has been almost entirely exhausted. Since the
process of oocyte loss occurs from apoptosis, it is presumed that
ceramide accumulation is responsible, at least in part, for this
observation. Moreover, work using acid sphingomyelinase
“knock-out” mice has shown that oocytes lacking this enzyme
are resistant to stimuli promoting apopotosis, presumably due to
a dysfunctional ceramide response [20]. Sperm from these same
mice also have lipid abnormalities, leading to profound
morphological and functional defects [21]. Thus, these and
other studies suggest that ceramide metabolism plays a key role
in gamete formation and function, perhaps explaining, at least in
part, observations described above on the AC knock-out mice.
8. Acid ceramidase and cancer
Based on the important role(s) of ceramide and sphingosine
in regulating cell growth, these sphingolipids have become
important targets in cancer therapy (for review see [22]).
Moreover, since AC is one of the key enzymes regulating
sphingolipid metabolism, several of these recent therapies have
been focused on this enzyme. For example, overexpression of
AC in murine L929 fibrosarcorma cells suppressed apoptotic
cell death induced by tumor necrosis factor alpha (TNFα) [23],
presumably by reducing ceramide levels. Moreover, a recom-
binant Sindbis virus (SV) expressing AC decreased intracellular
ceramide and protected cells from SV-induced apoptosis [24].
Conversely, inhibitors of AC activity may lead to increased
ceramide levels and stimulate apoptotic cell death. For example,
N-oleoylethanolamine, an inhibitor of AC activity, increased
ceramide formation and enhanced apoptosis in L929 cells [23],
and also enhanced tumor-induced apoptosis in dendritic cells
(DC) [25] and radiation-induced apoptosis in human glioma
cells [26]. In addition, N-oleoylethanolamine treatment led to
increased ceramide levels and TNF-α/IFN-α-induced apoptosis
in primary placental trophoblasts [27].Another inhibitor of AC, B13 (1R,2R or 1S,2S-(2-N-
myristoylamino-1-(4-nitrophenyl)-1,3-dihydroxypropan), has
been shown to induce apoptosis in prostate cancer cells [28].
Of particular importance, the growth of prostate cancer
xenografts was efficiently inhibited compared to conventional
radiation therapy when mice were treated with the combination
of B13 and radiation, defining a synergistic role for these
inhibitors with established cancer treatments. Treatment of
nude mice with B13 alone also prevented tumor growth using
two different aggressive human colon cancer cell lines
metastatic to the liver, without any toxicity to normal cells
[29].
Other ceramide analogs, (1S,2R)-2-N-myristoylamino-1-
phenyl-1-propanol (De-MAPP) and (1R,2R)-2-N-myristoyla-
mino-1-(4-nitrophenyl)-1,3-propandiol (D-NMAPPD), also
suppressed AC activity and led to the elevation of endogenous
ceramide levels. Subsequently, apoptosis was increased in
primary keratinocytes [30]. De-MAPP also enhanced nerve
growth factor-induced apoptotic cell death in hippocampal
neurons [31].
These findings and others suggest that the inhibition of AC
activity may serve as a useful target for cancer therapy, alone or
in combination with other anti-oncogenic treatments. However,
it is important to recognize that the mechanism(s) by which
these inhibitors are functioning, as well as their specificity
towards the individual ceramidases, remains unclear. For
example, De-MAPP has been reported to inhibit AC activity,
but also inhibits the activities of alkaline and/or neutral
ceramidases in some cell lines. Furthermore, N-oleoylethano-
lamine and B13 appear to have preferential inhibition towards
AC activity, but in some reports inhibition of other ceramidases
has been shown. Therefore, although the biological effects of
inhibiting ceramidase activities are well documented, it cannot
always be concluded from these studies which ceramidase(s) is
responsible for the effect. Also, in most cases the inhibitory
compounds have not been tested with pure enzymes, and thus
the mechanism of inhibition remains unknown. Lastly, and
quite importantly, lysosomal ceramide does not appear to play
an essential role in stress-induced apoptosis [32,33], or the
apoptosis induced by exogenous ceramide treatment [34].
Whether or not AC activity contributes to levels of non-
lysosomal ceramide also remains unknown, although it should
be noted that acid sphingomyelinase, another “lysosomal”
enzyme that closely associates with AC, certainly does (e.g.,
[35,36]). To better understand the role of AC in apoptosis, a
more complete understanding of its trafficking and subcellular
localization is certainly required, particularly in tumor cells and
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ization of the reagents used to inhibit AC activity is needed.
Also of interest, abnormal expression of endogenous AC has
been reported in several human cancers. For example, over-
expression of AC was reported in prostate cancers [37] and
melanomas [38]. In addition, high levels of AC mRNA, protein,
and activity were found in human alveolar macrophages that
have an extended lifespan compared to precursor monocytes.
Moreover, inhibition of AC activity induced cell death earlier
than expected in these macrophages [39]. These results also
suggest an important role of AC in tumorigenesis and/or in
prolonging the survival of human cells.
Thus, overall there appears to be a correlation between cell
growth and AC activity; i.e., high AC activity leads to reduced
ceramide levels and enhanced cell growth, while low AC
activity leads to reduced cell growth through an enhanced
ceramide response. However, it must be noted that there are
exceptions to this “simple” rule, such as decreased or shut-down
AC expression in thyroid [40] and gastrointestinal cancers [17].
Clearly, much more information is needed concerning the
function of AC in live cells, particularly with regard to the
enzyme's processing and subcellular trafficking, and how its
location in different cellular compartments influences down-
stream ceramide and sphingosine signaling events.
9. Acid ceramidase and other complex diseases
Aside from cancer, AC may play a role in the pathology of
other, important complex diseases. For example, recent studies
have shown that insulin resistance and type 2 diabetes result
from the accumulation of lipids in tissues not normally
associated with fat storage, and that free fatty acids inhibit
insulin stimulation of Akt/protein kinase B, a central regulator
of glucose uptake and anabolic metabolism through stimula-
tion of ceramide production [41]. Importantly, it also has been
shown that AC overexpression prevents the inhibitory effects
of saturated fatty acids on insulin signaling [42], presumably
through the reduction of ceramide. Of particular note, in this
study overexpression of AC not only reduced ceramide levels,
but also promoted accumulation of sphingosine.
In another recent publication it has been suggested that AC
might play a role in the etiology of Alzheimer's disease [43].
In this study the major glycoproteins from Alzheimer's disease
brains were obtained, and among these AC activity and protein
levels were significantly elevated. Immunohistochemical
staining indicated that accumulating AC was located mainly
in the cell bodies of neurons and co-localized with neurofi-
brillary tangles. These intriguing findings require further
investigation, but also suggest that AC-mediated signaling
pathways might be involved in the molecular mechanisms
leading to Alzheimer's disease.
10. Conclusions
AC plays a central role in sphingolipid metabolism,
particularly in controlling the levels of ceramide and
sphingosine in cells. Since its original description over40years ago, numerous advances have been made. A human
disease (FD) has been associated with AC deficiency, and the
first “knock-out” mouse model of AC deficiency has been
produced. The gene encoding AC has been obtained,
numerous mutations in this gene causing FD have been
identified, and large quantities of recombinant enzyme have
been produced and characterized. Several anti-AC antibodies
are also available and have been used to begin investigating
the cell biology of this important protein. However, despite
these important advances, much more information is required
to fully understand the role of AC in sphingolipid-mediated
signal transduction and human disease. Important questions
that will be addressed during the upcoming years include: (a)
how AC is trafficked in cells and the influence of its
subcellular location on the “forward” and “reverse” AC
activities, (b) how AC function is affected by its presence in
a multienzyme complex, (c) how AC influences fertilization
and early mammalian development, and (d) what role AC
plays in the etiology of complex human diseases. Moreover,
based on our continuing understanding of AC's biology and its
important role in the regulation of sphingolipid metabolism,
this enzyme is likely to continue to be a target for new drug
development in cancer and other disorders.
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